Can I Take Folate with Sermorelin?

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a synthetic 29-amino-acid peptide that mirrors the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells, triggering the pulsatile secretion of growth hormone (GH). GH then stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which drives the anabolic and metabolic effects patients typically seek.

FDA Status and Compounding Context

The original branded product Geref was discontinued in the United States in 2008 for commercial rather than safety reasons. Sermorelin is now available exclusively through 503A compounding pharmacies for individually patient-specific prescriptions. The FDA has not approved a currently marketed sermorelin product, so prescribing is off-label and governed by state pharmacy boards and USP 797 standards.

Why GH Axis Health Matters for Micronutrient Status

The GH/IGF-1 axis influences cellular proliferation, protein synthesis, and one-carbon metabolism. One-carbon metabolism is the network of biochemical reactions that depend directly on folate and B12 to generate methyl groups for DNA synthesis, repair, and methylation of key proteins. Disruptions in folate availability can theoretically reduce the cellular capacity to respond to IGF-1 signaling, though this link has not been tested in a randomized controlled trial specifically for sermorelin.

What Is Folate and Why Do Patients on Sermorelin Use It?

Folate is a water-soluble B vitamin (B9) found in leafy greens, legumes, and fortified foods. Its synthetic form, folic acid, is used in supplements and fortified foods. The biologically active form is 5-methyltetrahydrofolate (5-MTHF), which donates methyl groups in the methionine cycle and supports purine and pyrimidine synthesis required for DNA replication.

Patients pursuing sermorelin therapy often do so for body composition, recovery, and anti-aging goals. Many of those same patients take folate for:

• Cardiovascular protection via homocysteine lowering
• Support of methylation pathways (especially those with MTHFR C677T or A1298C variants)
• General B-vitamin optimization as part of a wellness stack
• Management of folate depletion caused by medications such as methotrexate, sulfasalazine, or anticonvulsants

The MTHFR Connection

The MTHFR (methylenetetrahydrofolate reductase) enzyme converts dietary folate and folic acid into 5-MTHF. Approximately 10-15% of individuals of European ancestry carry two copies of the C677T variant, producing an enzyme with roughly 30-40% of normal activity according to data published in the American Journal of Clinical Nutrition [1]. These individuals accumulate unmetabolized folic acid and have reduced circulating 5-MTHF. For them, supplementing with pre-methylated 5-MTHF rather than standard folic acid is the evidence-preferred approach [1].

Sermorelin therapy does not appear to worsen MTHFR-related folate impairment, but patients initiating a growth hormone secretagogue protocol who also carry MTHFR variants should confirm their folate form before adding any new supplement.

Is There a Pharmacokinetic Interaction Between Folate and Sermorelin?

No pharmacokinetic interaction between folate and sermorelin acetate has been documented in PubMed-indexed literature, the FDA Adverse Event Reporting System (FAERS), or Natural Medicines Comprehensive Database as of this writing.

Why the Two Are Unlikely to Interact Pharmacokinetically

Sermorelin is a peptide. After subcutaneous injection, it is absorbed rapidly, reaches peak plasma concentration within 5-20 minutes, and is cleared by peptidase degradation with a half-life of approximately 11-12 minutes [2]. It does not undergo hepatic CYP450 metabolism and is not renally excreted as an intact molecule.

Folate, by contrast, is absorbed in the proximal small intestine, transported via the reduced folate carrier, and distributed to tissues over hours. It is not a CYP enzyme substrate at physiological doses. Because the two compounds travel through entirely different metabolic and clearance pathways, the probability of a clinically significant pharmacokinetic interaction is extremely low.

Pharmacodynamic Considerations

A pharmacodynamic interaction is theoretically possible at the cellular level. IGF-1 (elevated by sermorelin) promotes cell proliferation. Proliferating cells require folate for de novo purine synthesis. If a patient is significantly folate-deficient, rapidly dividing tissues may have reduced substrate availability, potentially blunting the anabolic response to elevated IGF-1. This is a mechanistic hypothesis, not a demonstrated clinical finding, and it argues for maintaining adequate folate status rather than avoiding co-administration.

Folate, Homocysteine, and the GH Axis: What the Literature Says

Homocysteine and Growth Hormone

Elevated homocysteine is an independent cardiovascular risk marker. Homocysteine is remethylated to methionine by methionine synthase, a reaction that requires 5-MTHF as the methyl donor. GH deficiency in adults is associated with elevated homocysteine [3], and GH replacement therapy has been shown to reduce homocysteine concentrations in some studies. A 12-month open-label trial published in Clinical Endocrinology (N=30) found that GH replacement reduced mean plasma homocysteine from 14.2 to 11.6 micromol/L (P<0.05), an effect attributed partly to increased renal folate conservation [3].

If sermorelin raises GH and thereby IGF-1, the metabolic shift may modestly lower homocysteine. That would represent an additive benefit rather than a harmful interaction when folate is also being supplemented.

Folate Deficiency Impairs GH Secretion Indirectly

Severe folate deficiency leads to megaloblastic changes and systemic hypomethylation. The hypothalamic GHRH neurons depend on proper methylation of the GHRH gene promoter region for baseline transcription. Animal models of folate deficiency show reduced hypothalamic neuropeptide gene expression [4], though direct measurement of hypothalamic GHRH in folate-deficient humans has not been published. The clinical takeaway is to correct frank folate deficiency before expecting optimal sermorelin response.

Special Populations: When Co-Administration Needs Closer Monitoring

Patients on Anticonvulsants

Phenytoin, carbamazepine, and valproate all deplete folate through mechanisms including increased hepatic folate catabolism and impaired intestinal absorption. The American Academy of Neurology acknowledges folate supplementation in patients of reproductive age on anticonvulsants [5]. If such a patient is also on sermorelin, their prescribing clinician should verify serum folate and homocysteine at baseline and at 3 months.

Patients with MTHFR Variants

For these patients, folic acid supplementation can paradoxically raise unmetabolized folic acid levels while leaving 5-MTHF low. Switching to 400-1,000 mcg of 5-MTHF daily is typically preferred. Sermorelin does not appear to alter MTHFR enzyme activity, so the recommendation to use 5-MTHF is driven entirely by the MTHFR variant, not by the peptide.

Patients with Renal Impairment

Chronic kidney disease (CKD) reduces renal reabsorption of water-soluble vitamins. Folate loss in CKD is well-documented [6]. Sermorelin is not recommended in patients with significant renal impairment because GH signaling disturbances are common in CKD and peptide clearance may be unpredictable. If both conditions coexist, nephrology and endocrinology input is required before starting either agent.

Women Who Are Pregnant or Planning Pregnancy

Sermorelin is Category C. The standard pre-conception and first-trimester folate recommendation is 400-800 mcg daily to reduce neural tube defect risk; women with prior neural tube defect pregnancies require 4 mg daily per ACOG guidelines [7]. Sermorelin should generally not be used during pregnancy. Folate supplementation in this context follows standard obstetric guidance independent of any peptide therapy.

Practical Dosing and Timing Guidance

No clinical trial has established a required separation window between sermorelin and folate supplementation. The following recommendations are based on pharmacokinetic principles and general peptide-therapy practice:

Sermorelin Injection Timing

Sermorelin is typically prescribed at doses of 200-500 mcg subcutaneously at bedtime to mimic the physiologic nocturnal GH surge. Some protocols use twice-daily dosing (morning and bedtime). The 11-12 minute plasma half-life means sermorelin is effectively cleared within 1-2 hours post-injection.

Folate Supplement Timing

Folate is best absorbed with food and away from medications that may impair its uptake (such as proton pump inhibitors or antacids). Taking a folate supplement with breakfast or lunch, rather than at bedtime alongside sermorelin injection, is a reasonable practice that avoids any theoretical overlap, though no evidence confirms harm from simultaneous administration.

Recommended Starting Doses

• Sermorelin: per prescribing physician, typically 200-500 mcg subcutaneously nightly
• Folate (general adult): 400-800 mcg dietary folate equivalents daily (NIH Office of Dietary Supplements) [8]
• Folate for confirmed MTHFR homozygous C677T: 400-1,000 mcg of 5-MTHF daily, physician-directed

The HealthRX clinical team uses the following decision framework when a patient on sermorelin wants to add folate supplementation:

Step 1. Order baseline labs: serum folate, red blood cell (RBC) folate, homocysteine, CBC with differential, and IGF-1.

Step 2. Screen for MTHFR variants (C677T, A1298C) if not already done, particularly in patients with elevated homocysteine (>10 micromol/L) or prior history of folate-responsive conditions.

Step 3. Select folate form. Standard folic acid is acceptable for most patients. Choose 5-MTHF for confirmed MTHFR compound heterozygotes or homozygotes, patients on anticonvulsants, or those with persistently elevated homocysteine despite folic acid supplementation.

Step 4. Recheck serum folate and homocysteine at 8-12 weeks. Recheck IGF-1 at 3 months on sermorelin per standard protocol.

Step 5. Adjust sermorelin dose based on IGF-1 target (typically mid-normal range for age, per endocrinology guidance), not based on folate status.

Monitoring Labs During Combined Use

Standard sermorelin monitoring includes IGF-1 at baseline and at 3-month intervals, fasting glucose, and a symptom review for edema, carpal tunnel symptoms, and injection-site reactions. Adding folate to the monitoring panel requires minimal extra blood draw. Suggested combined monitoring schedule:

• Baseline: IGF-1, fasting glucose, CBC, serum folate, RBC folate, homocysteine, comprehensive metabolic panel (CMP)
• 8-12 weeks: Serum folate, homocysteine, IGF-1
• 6 months: Full repeat panel plus thyroid function (TSH, free T4) given that GH can influence thyroid binding proteins [9]
• Annually: Full metabolic reassessment

A 2021 review in Endocrine Reviews noted that "comprehensive micronutrient assessment is underutilized in patients receiving growth hormone secretagogue therapy, despite the known interdependence of one-carbon metabolism and anabolic signaling" [9]. That observation supports a proactive approach to folate monitoring in sermorelin patients.

What About Other B Vitamins in the Same Stack?

Patients combining sermorelin and folate often also take B12, B6, or a B-complex. This matters because folate and B12 work together in the methionine cycle. B12 deficiency can produce elevated homocysteine even when folate is adequate, because methionine synthase requires both.

B12 and Sermorelin

No interaction between cobalamin (B12) and sermorelin has been published. B12 is not a CYP substrate and does not alter peptide clearance. Checking serum B12 alongside folate at baseline is good practice, particularly in patients over 50, vegans, or those on metformin (which reduces B12 absorption by approximately 19% at standard doses, per a 2019 Diabetes Care analysis [10]).

Pyridoxine (B6)

B6 is a cofactor for cystathionine beta-synthase in the transsulfuration pathway, which converts homocysteine to cystathionine. Supplementing B6 alongside folate and B12 produces additive homocysteine lowering. No interaction with sermorelin is expected.

Potential Red Flags to Report to Your Prescriber

While folate and sermorelin are not expected to interact adversely, patients should report the following to their prescribing provider:

• Persistent fatigue, pallor, or glossitis (possible folate or B12 deficiency despite supplementation)
• Edema or joint pain (possible GH excess from sermorelin)
• Injection-site nodules lasting more than 72 hours
• Visual changes or severe headache (rare but serious GH-related adverse effects)
• Any new prescription medications, particularly anticonvulsants, methotrexate, or sulfasalazine, which are known folate antagonists

Summary of Interaction Risk Level

The overall interaction risk between folate supplementation and sermorelin acetate is low based on available evidence. The two compounds do not share metabolic pathways that would produce pharmacokinetic competition. A pharmacodynamic benefit, where adequate folate supports the cellular response to IGF-1, is mechanistically plausible. The populations that need closer monitoring are those with MTHFR variants, anticonvulsant users, patients with renal impairment, and pregnant or potentially pregnant women.

Patients already taking both do not need to stop either medication pending lab results, but a baseline folate and homocysteine panel should be ordered at the next clinical encounter if not already available.